Zacks Investment Research·17h ago
Bet On These 5 Top-Ranked Stocks With Increasing P/E RatiosTap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.
HeartBeam, Inc.(BEAT)Earnings, Financials & Key Ratios
BEAT•NASDAQ
$0.66
Price updated Jul 7, 2026
AboutHeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.Show more
- Revenue$0
- EBITDA-$21M-6.1%
- Net Income-$21M-8.1%
- EPS (Diluted)-0.62+15.1%
- ROE-987.32%-346.5%
BEAT Price & Volume
HeartBeam, Inc. (BEAT) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Development Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary Regulatory Approval Risk
Key Thesis Takeaways
- HeartBeam remains in a high-risk, pre-revenue developmental stage characterized by consistent quarterly operating losses of approximately $5 million and a rapidly depleting capital base.
- While the company continues to prioritize R&D, the lack of commercial revenue and a deteriorating current ratio of 0.74 suggest that the firm faces significant liquidity challenges.
- Investors should monitor the company's ability to secure additional financing, as the current cash position of $2.0 million is insufficient to sustain the historical quarterly burn rate.
Verdict Logic
the company's cash position of $2.0 million against a quarterly operating loss of $4.7 million in 2026Q1 indicates a critical liquidity shortfall that likely necessitates dilutive financing.
BEAT Growth Metrics
HeartBeam, Inc. (BEAT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM0.47%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM22.97%
Return on Capital
10 Years-172.18%
5 Years-320.92%
3 Years-462.17%
Last Year-993.14%
BEAT Recent Earnings
HeartBeam, Inc. (BEAT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.12+14.3%
$0.14
Rev
$100,000-33.2%
$149,750
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.14-7.7%
$0.13
Rev
—
$1M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.15+6.3%
$0.16
Rev
—
$875,000
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.15+6.3%
$0.16
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.12vs $0.14+14.3% | $100,000vs $149,750-33.2% |
| Q2 2026 | Mar 12, 2026 | $0.14vs $0.13-7.7% | —vs $1M |
| Q4 2025 | Nov 13, 2025 | $0.15vs $0.16+6.3% | —vs $875,000 |
| Q3 2025 | Aug 13, 2025 | $0.15vs $0.16+6.3% | — |
Based on last 12 quarters of dataView full earnings history →
Latest BEAT News
Recent stock market news and headlines for HeartBeam, Inc. (BEAT)
Business Wire·Jun 30, 2026
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of ScheduleSANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule.
Business Wire·Jun 24, 2026
HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership TransitionSANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition.
Peers Comparison
Key metrics vs top competitors for HeartBeam, Inc. (BEAT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.66 | $22.7M | -1.06 | — | — | -987.32% | — | |
| $28.00 | $75.5M | 0.97 | 12.07% | 23.84% | 284.31% | — | |
| $1.84 | $107.43M | -0.99 | 1057.12% | -1427.15% | -155.31% | — | |
| $570.25 | $45.29B | 43.60 | 10.42% | 24.63% | 70.87% | — | |
| $125.09 | $4.11B | -89.99 | 26.24% | -3.53% | -20.6% | — | |
| $7.58 | $1.98B | -24.45 | 18.96% | -73.63% | -36.79% | — |
Compare BEAT vs Peers
HeartBeam, Inc. (BEAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BEAT SEC Filings & Documents
HeartBeam, Inc. (BEAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 16, 2026·SEC
Material company update
Nov 21, 2025·SEC
Material company update
Jul 16, 2025·SEC
10-K Annual Reports
510-Q Quarterly Reports
6Get notified when BEAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BEAT Frequently Asked Questions
HeartBeam, Inc. (BEAT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BEAT profitable?
HeartBeam, Inc. (BEAT) reported a net loss of $20.2M for fiscal year 2025.
Dividend & Returns
What is BEAT's return on equity?
HeartBeam, Inc. (BEAT) has a return on equity (ROE) of -987.3%. Negative ROE indicates the company is unprofitable.
What is HeartBeam, Inc.'s free cash flow?
HeartBeam, Inc. (BEAT) had negative free cash flow of $14.0M in fiscal year 2025, likely due to heavy capital investments.